Plain-English translation of NCT06269432 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial studied whether measuring how well a patient's blood clots respond to aspirin could help doctors choose the best antiplatelet medication to prevent another stroke. Researchers compared two approaches: one group received personalized medication selection based on blood clotting tests, while another group received standard aspirin treatment. The study involved 1,224 people who had experienced a recent stroke.
Even when patients take aspirin or clopidogrel as prescribed, some people's blood continues to clot too easily, putting them at risk for another stroke. This trial investigated whether blood clotting tests could identify these patients earlier and help doctors switch to more effective medications before another stroke happens.
Participants in the precision group underwent blood tests to measure how well their blood clotted in response to medication, and doctors adjusted their antiplatelet therapy based on these results. The control group continued taking standard aspirin 100mg once daily. Both groups were monitored over time to see whether personalized treatment based on blood clotting tests reduced the risk of having another stroke compared to standard treatment alone.
AI-generated summary from trial data · Jun 19, 2026 · Not medical advice
China